Skip to main content
. 2020 Jan 1;11(6):1383–1392. doi: 10.7150/jca.32552

Figure 1.

Figure 1

The downregulation of TCL6 expression was associated with poor prognosis of patients. A. The expression of TCL6 was decreased in RCC tissues (523 cases) compared to the normal tissues (100 cases), which of data was collected from the TCGA database and analyzed by GEPIA platform. B. The TCL6 expression data of RCC (n=448) and normal (n=67) tissues were further analyzed by online TANRIC platform. C. We further analyzed the expression levels of TCL6 in seventy-two RCC and match normal tissues obtained from the GEO database (GSE53757dataset). D. The expression of TCL6 gradually decreased among the different clinical stages of renal cancer (by one-way analysis of variance). Data are shown as means ± SD. Kaplan-Meier curves showed the patient overall survival (E) and disease-free survival (F) of the high TCL6 expression and low TCL6 expression. These graphs were conducted by TANRIC platform. Dotted line: the 95% confidence interval (CI). G. Low level of TCL6 expression was associated with poor overall survival of patients with renal cancer. *P<0.05.